Table. 7—

Pharmacoeconomic and symptom resolution assessments: clinically and microbiologically evaluable populations

Uncomplicated groupComplicated group
Total TDI#,¶
 Clinically evaluable+1.3±2.4 (120)1.3±2.5 (22)0.891ƒ0.9±2.2 (107)0.5±1.9 (113)0.036
 Microbiologically evaluable+1.5±2.6 (66)1.0±2.5 (69)0.8000.9±2.3 (75)0.7±1.8 (79)0.099
Patients with improvement in respiratory symptoms by day 3§ %
 Clinically evaluable63.8 (116)50.4 (121)0.049##57.0 (109)62.2 (110)0.465
 Microbiologically evaluable70.3 (64)49.3 (73)0.01558.8 (78)65.7 (77)0.483
Respiratory healthcare utilisation##
 Clinically evaluable n143151120126
  Hospitalisation %011.000##020.247
  Nonstudy medical visits %310.203360.335
  Additional antibacterial use %8150.04731330.685
 Microbiologically evaluable n80878689
  Hospitalisation %011.000030.246
  Nonstudy medical visits %111.000060.060
  Additional antibacterial use %6160.05329350.424
  • Data are presented as mean±sd (n) or % (n), unless otherwise stated. Levo.: levofloxacin; azithro.: azithromycin; amox.: amoxicillin; clav.: clavulanate; TDI: transition dyspnoea index. #: the TDI total change score is scored on a scale from −9 to +9, where a positive number indicates improvement; : clinically evaluable; +: based on patients who completed assessment; §: daily diary entries (cough, breathlessness and sputum production), where improvement is defined as a one-point reduction in the total symptom score; ƒ: based on the Wilcoxon rank-sum test, two-sided; ##: based on the Fisher's exact test.